Azilsartan medoxomil-CLD phase 3 study outcomes in systolic blood circulation pressure presented at ASH 2011 Takeda Global Research & Advancement Middle, Inc. U.S lilly cialis 5mg read more ., today announced outcomes from three phase 3 research of the investigational fixed-dose mix of azilsartan medoxomil plus chlorthalidone . In two stage 3 research, azilsartan medoxomil mixed in a fixed-dosage with CLD reduced clinic systolic blood circulation pressure more than the fixed-dose mix of olmesartan medoxomil plus hydrochlorothiazide .